Pfizer Inc

10-K

Quantli Newsdesk

· 4 months ago

Pfizer reported $62.6 billion in revenues for 2025, down 2%, as COVID-19 product sales collapsed 59% for Paxlovid and 20% for Comirnaty. Adjusted diluted EPS rose 4% to $3.22 despite the revenue decline, driven by $5.7 billion in cost savings from restructuring initiatives. The company faces a significant patent cliff from 2026-2030 and increasing pricing pressure from the IRA Medicare drug price negotiation program.